US › Healthcare

Compass Therapeutics Inc. (CMPX)

US · Healthcare · Biotechnology

$0.86-4.09%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-25.2M

EPS

$-0.13

EPS estimate

$-0.10

EPS came in at -0.13 against a street estimate of -0.10 — a miss of 30.0%.

Key statistics

Market cap

$158.3M

Forward P/E

0.0

P/B

1.27

Book value

$0.92

EPS (TTM)

$-0.40

52-week high

$6.88

52-week low

$0.82

50-day MA

$1.81

200-day MA

$3.46

Beta

0.91

Analyst view

Analysts rate Compass Therapeutics Inc. a buy (12 buy, 3 hold, 0 sell out of 15) with an average price target of $5.45.

Shareholding

Insiders

12.47%

Institutions

88.51%

Largest institutional holders

Fund	Stake
TANG CAPITAL MANAGEMENT LLC	9.99%
Orbimed Advisors LLC	8.45%
Suvretta Capital Management, LLC	7.83%
BlackRock Inc	6.26%
State Street Corp	5.53%
Enavate Sciences GP, LLC	4.32%
Vivo Capital, LLC	4.31%
Vanguard Capital Management, LLC	3.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Compass Therapeutics Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.